A Major Step Forward: Ocugen Launches Phase 2/3 Trial of OCU410ST for Stargardt Disease

At A Race Against Blindness, we’re always following scientific breakthroughs that bring hope to families affected by rare retinal diseases. One of the most exciting recent updates comes from Ocugen, Inc. , a biotechnology company developing cutting-edge gene therapies. On June 16, 2025 , Ocugen announced that the U.S. Food and Drug Administration (FDA) has cleared them to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST , their modifier gene therapy candidate for Stargardt disease . This is a major step toward a potential treatment for a condition that currently has no approved therapies. What Makes OCU410ST Different Unlike traditional gene therapy approaches that target single mutations, OCU410ST uses Ocugen’s modifier gene therapy platform . This approach delivers the RORA gene , which regulates multiple disease pathways linked to Stargardt disease, including: Lipofuscin buildup Oxidative stress Inflammation Cell survival Because it targets broad disease mechanisms, OCU410ST may help a wide range of patients, even though Stargardt and related ABCA4-retinopathies involve ov